Fundraising FoxSeraGene Therapeutics
2 known investors
Find your way into SeraGene Therapeutics
Sign up to see every warm intro you have to SeraGene Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the SeraGene Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
SeraGene Therapeutics is a pre-clinical stage biotech company developing RNA (siRNA) and nanomedicine-based therapies for coagulation disorders, including rare bleeding disorders, platelet dysfunction, and thrombotic disorders. It aims to provide long-lasting, low-burden prophylactic treatments for patients living with chronic coagulation conditions.
Investors · 2
Pathway to Cureslisted by Pathway to CuresNew York
How we know: Pathway to Cures's portfolio page · funding news · finsmes.com · Not right? Tell us
Foresite CapitalreportedWest Hollywood
How we know: funding news · Not right? Tell us
Frequently asked questions
- What does SeraGene Therapeutics do?
- SeraGene Therapeutics is a pre-clinical stage biotech company developing RNA (siRNA) and nanomedicine-based therapies for coagulation disorders, including rare bleeding disorders, platelet dysfunction, and thrombotic disorders. It aims to provide long-lasting, low-burden prophylactic treatments for patients living with chronic coagulation conditions.
- Who are SeraGene Therapeutics's investors?
- SeraGene Therapeutics's investors include Pathway to Cures, Foresite Capital.